Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: An observational study

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Beghé, Bianca ^a   Verduri, Alessia ^a   Bottazzi, Barbara ^b,c   Stendardo, Mariarita ^d   Fucili, Alessandro ^d   Balduzzi, Sara ^a   Leuzzi, Chiara ^a   Papi, Alberto ^d   Mantovani, Alberto ^b,c   Fabbri, Leonardo M ^a   Ceconi, Claudio ^d   Boschetto, Piera ^d  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 1BETA; PENTRAXIN 3;

AGED; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; SMOKING; SPIROMETRY;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, INTERLEUKIN-1 TYPE II; SERUM AMYLOID P-COMPONENT; SMOKING; SPIROMETRY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84893186495     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080166     Document Type: Article

References (33)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2012) Available: http://www.goldcopd.org/. Accessed 2013 August 30.
2. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33: 1787-1847. doi:10.1093/eurheartj/ehs104. PubMed: 22611136.
3. Boschetto P, Beghé B, Fabbri LM, Ceconi C (2012) Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology 17: 422-431. doi:10.1111/j.1440-1843.2011. 02118.x. PubMed: 22142519.
4. Fabbri LM, Luppi F, Beghé B, Rabe KF (2008) Complex chronic comorbidities of COPD. Eur Respir J 31: 204-212. doi:10.1183/09031936.00114307. PubMed: 18166598.
5. Ukena C, Mahfoud F, Kindermann M, Kindermann I, Bals R et al. (2010) The cardiopulmonary continuum systemic inflammation as 'common soil' of heart and lung disease. Int J Cardiol 145: 172-176. doi:10.1016/j.ijcard.2010.04.082. PubMed: 20570377.
6. Alonso-Martínez JL, Llorente-Diez B, Echegaray-Agara M, Olaz- Preciado F, Urbieta-Echezarreta M et al. (2002) C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 4: 331-336. doi:10.1016/S1388-9842(02)00021-1. PubMed: 12034159. (Pubitemid 35190358)
7. Latini R, Gullestad L, Masson S, Nymo SH, Ueland T et al. (2012) Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail 14: 992-999. doi:10.1093/eurjhf/hfs092. PubMed: 22740508.
8. Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6: 232-241. doi:10.1038/nrrheum.2010.4. PubMed: 20177398.
9. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH et al. (2005) Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 26: 1887-1894. doi:10.1093/eurheartj/ehi291. PubMed: 15860516. (Pubitemid 41253302)
10. Mascarenhas J, Lourenço P, Lopes R, Azevedo A, Bettencourt P (2008) Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 155: 521-525. doi:10.1016/j.ahj.2007.10.040. PubMed: 18294490. (Pubitemid 351255605)
11. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C et al. (2010) The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 12: 685-691. doi:10.1093/eurjhf/hfq050. PubMed: 20395261.
12. Boschetto P, Fucili A, Stendardo M, Malagù M, Parrinello G et al. (2013) Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. Respirology 18: 125-130. doi:10.1111/j.1440-1843.2012.02264.x. PubMed: 22985248.
13. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R et al. (2005) Standardisation of spirometry. Eur Respir J 26: 319-338. doi:10.1183/09031936. 05.00034805. PubMed: 16055882. (Pubitemid 41079078)
14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med 166: 111-117. doi:10.1164/ajrccm.166.1.at1102. PubMed: 12091180
15. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D et al. (2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110: 2349-2354. doi:10.1161/01.CIR.0000145167.30987.2E. PubMed: 15477419. (Pubitemid 39407338)
16. Müller B, Peri G, Doni A, Perruchoud AP, Landmann R et al. (2002) High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 72: 643-649. PubMed: 12377932. (Pubitemid 36277834)
17. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG et al. (2009) Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 11: 130-139. doi:10.1093/eurjhf/hfn013. PubMed: 19168510.
18. Güder G, Brenner S, Angermann CE, Ertl G, Held M et al. (2012) GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res 13: 13. doi:10.1186/1465-9921-13-13. PubMed: 22309369.
19. Flu WJ, van Gestel YR, van Kuijk JP, Hoeks SE, Kuiper R et al. (2010) Co-existence of COPD and left ventricular dysfunction in vascular surgery patients. Respir Med 104: 690-696. doi:10.1016/j.rmed.2009.11.013. PubMed: 20005086.
20. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G et al. (2012) Unrecognised ventricular dysfunction in COPD. Eur Respir J 39: 51-58. doi:10.1183/09031936.00044411. PubMed: 21700606.
21. Freixa X, Portillo K, Paré C, Garcia-Aymerich J, Gomez FP et al. (2013) Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J 41: 784-791. doi:10.1183/09031936.00222511. PubMed: 23018914.
22. Chapman KR, Smith DL, Rebuck AS, Leenen FH (1985) Hemodynamic effects of inhaled ipratropium bromide, alone and combined with an inhaled beta 2-agonist. Am Rev Respir Dis 132: 845-847. PubMed: 2864891. (Pubitemid 16247751)
23. Van Pottelberge GR, Bracke KR, Pauwels NS, Vermassen FE, Joos GF et al. (2012) COPD is associated with reduced pulmonary interstitial expression of pentraxin-3. Eur Respir J 39: 830-838. doi:10.1183/09031936.00138110. PubMed: 21920889.
24. Aaron SD, Angel JB, Lunau M, Wright K, Fex C et al. (2001) Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163: 349-355. doi:10.1164/ajrccm.163.2.2003122. PubMed: 11179105. (Pubitemid 32158511)
25. Chung KF (2001) Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 34: 50s-59s. PubMed: 12392035.
26. Sapey E, Bayley D, Ahmad A, Newbold P, Snell N et al. (2008) Interrelationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability. Thorax 63: 493-499. doi:10.1136/thx.2007.086751. PubMed: 18057097. (Pubitemid 351831157)
27. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J et al. (2007) Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 62: 595-601. doi:10.1136/thx.2006.064428. PubMed: 17356059. (Pubitemid 47056886)
28. Sapey E, Ahmad A, Bayley D, Newbold P, Snell N et al. (2009) Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol 29: 508-516. doi:10.1007/s10875-009-9286-8. PubMed: 19291375.
29. Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P (2001) Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 22: 328-336. doi:10.1016/S1471-4906(01)01941-X. PubMed: 11377293. (Pubitemid 32675247)
30. Dentener MA, Creutzberg EC, Schols AM, Mantovani A, van't Veer C et al. (2001) Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 56: 721-726. doi:10.1136/thorax.56.9.721. PubMed: 11514694. (Pubitemid 32831700)
31. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM (1996) Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 77: 723-727. doi:10.1016/S0002-9149(97)89206-5. PubMed: 8651123. (Pubitemid 26116687)
32. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F et al. (1996) Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28: 964-971. doi:10.1016/S0735-1097(96)00268-9. PubMed: 8837575. (Pubitemid 26348163)
33. Cappuzzello C, Di Vito L, Melchionna R, Melillo G, Silvestri L et al. (2011) Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-gamma in patients with chronic heart failure. J Transl Med 9: 28. doi:10.1186/1479- 5876-9-28. PubMed: 21418620.